Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-7035 in KRAS G12D-Mutated Advanced CRC or PDAC
NCT07859085Phase 1Not yet recruiting
- Sponsor
- Genentech
- Start
- Oct 2026
- Primary completion
- Mar 2029
01
Overview
Phase 1, randomised trial of GDC-7035 in colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) (4 arms), sponsored by Genentech. Primary endpoints: Adverse Events at 30 months and Treatment-Emergent Adverse Events at Day 28. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
GDC-7035
03
Conditions
colorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07859085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07859085.